NILOTINIB HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nilotinib Hydrochloride, and when can generic versions of Nilotinib Hydrochloride launch?
Nilotinib Hydrochloride is a drug marketed by Apotex and is included in one NDA.
The generic ingredient in NILOTINIB HYDROCHLORIDE is nilotinib hydrochloride. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nilotinib hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NILOTINIB HYDROCHLORIDE?
- What are the global sales for NILOTINIB HYDROCHLORIDE?
- What is Average Wholesale Price for NILOTINIB HYDROCHLORIDE?
Summary for NILOTINIB HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 40 |
Clinical Trials: | 200 |
Patent Applications: | 153 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NILOTINIB HYDROCHLORIDE at DailyMed |
![NILOTINIB HYDROCHLORIDE drug patent expirations Drug patent expirations by year for NILOTINIB HYDROCHLORIDE](/p/graph/s/t/NILOTINIB_HYDROCHLORIDE-patent-expirations.png)
Recent Clinical Trials for NILOTINIB HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
H. Jean Khoury Cure CML Consortium | Phase 2 |
Sun Pharmaceuticals Industries Limited | Phase 3 |
KeifeRx, LLC | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for NILOTINIB HYDROCHLORIDE
Paragraph IV (Patent) Challenges for NILOTINIB HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TASIGNA | Capsules | nilotinib hydrochloride | 50 mg | 022068 | 1 | 2019-10-17 |
TASIGNA | Capsules | nilotinib hydrochloride | 150 mg and 200 mg | 022068 | 1 | 2013-11-08 |
US Patents and Regulatory Information for NILOTINIB HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apotex | NILOTINIB HYDROCHLORIDE | nilotinib hydrochloride | CAPSULE;ORAL | 203640-001 | Jan 5, 2024 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | NILOTINIB HYDROCHLORIDE | nilotinib hydrochloride | CAPSULE;ORAL | 203640-002 | Jan 5, 2024 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apotex | NILOTINIB HYDROCHLORIDE | nilotinib hydrochloride | CAPSULE;ORAL | 203640-003 | Jan 5, 2024 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |